NO20051351L - Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS - Google Patents

Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Info

Publication number
NO20051351L
NO20051351L NO20051351A NO20051351A NO20051351L NO 20051351 L NO20051351 L NO 20051351L NO 20051351 A NO20051351 A NO 20051351A NO 20051351 A NO20051351 A NO 20051351A NO 20051351 L NO20051351 L NO 20051351L
Authority
NO
Norway
Prior art keywords
enos
polypeptides
wild
limbs
type
Prior art date
Application number
NO20051351A
Other languages
English (en)
Norwegian (no)
Inventor
Katalin Kauser
Gabor Rubanyi
William P Dole
Hu Sheng Qian
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051351L publication Critical patent/NO20051351L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20051351A 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS NO20051351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363702P 2002-08-16 2002-08-16
PCT/US2003/025626 WO2004016761A2 (fr) 2002-08-16 2003-08-15 Therapie genique pour l'ischemie aigue des membres avec enos de type sauvage ou mutant

Publications (1)

Publication Number Publication Date
NO20051351L true NO20051351L (no) 2005-04-28

Family

ID=31888259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051351A NO20051351L (no) 2002-08-16 2005-03-15 Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS

Country Status (15)

Country Link
US (1) US20040120930A1 (fr)
EP (1) EP1536689A4 (fr)
JP (1) JP2005539031A (fr)
KR (1) KR20050042162A (fr)
CN (2) CN101391105A (fr)
AU (1) AU2003263844A1 (fr)
BR (1) BR0313515A (fr)
CA (1) CA2494845A1 (fr)
IL (1) IL166362A0 (fr)
MX (1) MXPA05001763A (fr)
NO (1) NO20051351L (fr)
PL (1) PL375446A1 (fr)
RU (1) RU2005107414A (fr)
WO (1) WO2004016761A2 (fr)
ZA (1) ZA200502181B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123749A1 (fr) * 2013-01-30 2014-08-14 Board Of Regents Of The University Of Nebraska Compositions et procédés pour le traitement de complications associées au diabète
KR102624967B1 (ko) * 2016-04-29 2024-01-16 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
CN105944243A (zh) * 2016-05-12 2016-09-21 段俊丽 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置
IL270388B2 (en) * 2017-05-02 2024-03-01 Univ Miami A method for treating ischemic tissue
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045775A1 (fr) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions et methodes modulant la vascularisation
EP1016726A1 (fr) * 1998-12-30 2000-07-05 Introgene B.V. Thérapie génique pour la promotion de l' angiogenèse
MXPA01010459A (es) * 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.

Also Published As

Publication number Publication date
WO2004016761A3 (fr) 2005-03-17
AU2003263844A1 (en) 2004-03-03
MXPA05001763A (es) 2005-08-19
CN1688197A (zh) 2005-10-26
IL166362A0 (en) 2006-01-16
EP1536689A2 (fr) 2005-06-08
CA2494845A1 (fr) 2004-02-26
JP2005539031A (ja) 2005-12-22
CN101391105A (zh) 2009-03-25
US20040120930A1 (en) 2004-06-24
CN100408101C (zh) 2008-08-06
EP1536689A4 (fr) 2006-09-06
KR20050042162A (ko) 2005-05-04
RU2005107414A (ru) 2006-01-27
BR0313515A (pt) 2005-10-18
ZA200502181B (en) 2006-09-27
PL375446A1 (en) 2005-11-28
WO2004016761A2 (fr) 2004-02-26

Similar Documents

Publication Publication Date Title
Keller et al. Population genomic signatures of divergent adaptation, gene flow and hybrid speciation in the rapid radiation of L ake V ictoria cichlid fishes
Paetkau et al. Genetic assignment methods for the direct, real‐time estimation of migration rate: a simulation‐based exploration of accuracy and power
Evanno et al. Detecting the number of clusters of individuals using the software STRUCTURE: a simulation study
Kass et al. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias
Mallick et al. The light skin allele of SLC24A5 in South Asians and Europeans shares identity by descent
Burchard et al. The importance of race and ethnic background in biomedical research and clinical practice
Rees et al. Understanding the evolution of human pigmentation: recent contributions from population genetics
Gligor et al. Hybridization between mouse lemurs in an ecological transition zone in southern Madagascar
NO20051351L (no) Genterapi for kritisk iskemi i lemmer med villtype eller mutante eNOS
Lopez et al. The interplay between natural selection and susceptibility to melanoma on allele 374F of SLC45A2 gene in a South European population
Ayyadevara et al. Lifespan extension in hypomorphic daf‐2 mutants of Caenorhabditis elegans is partially mediated by glutathione transferase CeGSTP2‐2
Chain et al. Duplicate gene evolution and expression in the wake of vertebrate allopolyploidization
Thompson et al. Rapid evolution of a voltage-gated sodium channel gene in a lineage of electric fish leads to a persistent sodium current
Nekrutenko et al. Oscillating evolution of a mammalian locus with overlapping reading frames: an XLαs/ALEX relay
Ridge et al. Mitochondrial genomic variation associated with higher mitochondrial copy number: the Cache County Study on Memory Health and Aging
Tang et al. Joint testing of genotype and ancestry association in admixed families
Sadrieh et al. Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram
Mao et al. Whole‐genome SNP data unravel population structure and signatures of selection for black plumage of indigenous chicken breeds from Jiangxi province, China
Sandra et al. Emery‐Dreifuss muscular dystrophy type 4: A new SYNE1 mutation associated with hypertrophic cardiomyopathy masked by a perinatal distress‐related spastic diplegia
Chavhan et al. Interplay of population size and environmental fluctuations: A new explanation for fitness cost rarity in asexuals
Park‐Holohan et al. Mechanics of myosin function in white muscle fibres of the dogfish, Scyliorhinus canicula
Jons et al. Mutations in Conserved Amino Acids in the KCNQ1 Channel and Risk of Cardiac Events in Type‐1 Long‐QT Syndrome
Martin Benchmarking protein–protein interface predictions: Why you should care about protein size
Pimsler et al. Population genomics reveals a candidate gene involved in bumble bee pigmentation
Pérez‐Pereira et al. Prediction of fitness under different breeding designs in conservation programs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application